Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Testing av tillegg av MEDI4736 (Durvalumab) til kjemoterapi før kirurgi for pasienter med høygradig øvre urinveiskreft

29. oktober 2026 oppdatert av: National Cancer Institute (NCI)

En fase II/III-studie av MEDI4736 (Durvalumab) og kjemoterapi for pasienter med høygradig øvre del av urinrøret før nefroureterektomi

This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).

SECONDARY OBJECTIVES:

I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)

OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.

ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.

After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.

Studietype

Intervensjonell

Registrering (Antatt)

131

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Kingman, Arizona, Forente stater, 86401
        • Rekruttering
        • Kingman Regional Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Khawaja S. Jahangir
    • Arkansas
      • Fort Smith, Arkansas, Forente stater, 72903
        • Suspendert
        • Mercy Hospital Fort Smith
      • Little Rock, Arkansas, Forente stater, 72205
        • Aktiv, ikke rekrutterende
        • University of Arkansas for Medical Sciences
    • California
      • Auburn, California, Forente stater, 95602
        • Aktiv, ikke rekrutterende
        • Sutter Auburn Faith Hospital
      • Berkeley, California, Forente stater, 94704
        • Aktiv, ikke rekrutterende
        • Alta Bates Summit Medical Center-Herrick Campus
      • Duarte, California, Forente stater, 91010
        • Aktiv, ikke rekrutterende
        • City of Hope Comprehensive Cancer Center
      • Fremont, California, Forente stater, 94538
        • Aktiv, ikke rekrutterende
        • Palo Alto Medical Foundation-Fremont
      • La Jolla, California, Forente stater, 92093
        • Rekruttering
        • UC San Diego Moores Cancer Center
        • Hovedetterforsker:
          • Aditya Bagrodia
        • Ta kontakt med:
      • Modesto, California, Forente stater, 95355
        • Aktiv, ikke rekrutterende
        • Memorial Medical Center
      • Mountain View, California, Forente stater, 94040
        • Aktiv, ikke rekrutterende
        • Palo Alto Medical Foundation-Camino Division
      • Palo Alto, California, Forente stater, 94304
        • Rekruttering
        • Stanford Cancer Institute Palo Alto
        • Hovedetterforsker:
          • Ali R. Khaki
        • Ta kontakt med:
      • Palo Alto, California, Forente stater, 94301
        • Aktiv, ikke rekrutterende
        • Palo Alto Medical Foundation Health Care
      • Roseville, California, Forente stater, 95661
        • Aktiv, ikke rekrutterende
        • Sutter Roseville Medical Center
      • Sacramento, California, Forente stater, 95816
        • Aktiv, ikke rekrutterende
        • Sutter Medical Center Sacramento
      • San Diego, California, Forente stater, 92103
        • Rekruttering
        • UC San Diego Medical Center - Hillcrest
        • Hovedetterforsker:
          • Aditya Bagrodia
        • Ta kontakt med:
      • San Francisco, California, Forente stater, 94115
        • Aktiv, ikke rekrutterende
        • California Pacific Medical Center-Pacific Campus
      • Santa Cruz, California, Forente stater, 95065
        • Aktiv, ikke rekrutterende
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Rosa, California, Forente stater, 95403
        • Aktiv, ikke rekrutterende
        • Sutter Pacific Medical Foundation
      • Sunnyvale, California, Forente stater, 94086
        • Aktiv, ikke rekrutterende
        • Palo Alto Medical Foundation-Sunnyvale
      • Vallejo, California, Forente stater, 94589
        • Aktiv, ikke rekrutterende
        • Sutter Solano Medical Center/Cancer Center
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • UCHealth University of Colorado Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 720-848-0650
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Denver, Colorado, Forente stater, 80206
        • Rekruttering
        • UCHealth - Cherry Creek
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Fort Collins, Colorado, Forente stater, 80524
        • Rekruttering
        • Poudre Valley Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 970-297-6150
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Fort Collins, Colorado, Forente stater, 80528
        • Rekruttering
        • Cancer Care and Hematology-Fort Collins
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Greeley, Colorado, Forente stater, 80631
        • Rekruttering
        • UCHealth Greeley Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Highlands Ranch, Colorado, Forente stater, 80129
        • Rekruttering
        • UCHealth Highlands Ranch Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 720-848-0650
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Lone Tree, Colorado, Forente stater, 80124
        • Rekruttering
        • UCHealth Lone Tree Health Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elizabeth R. Kessler
      • Loveland, Colorado, Forente stater, 80538
        • Rekruttering
        • Medical Center of the Rockies
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 970-203-7083
        • Hovedetterforsker:
          • Elizabeth R. Kessler
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20016
        • Rekruttering
        • Sibley Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jean H. Hoffman-Censits
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • MedStar Washington Hospital Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 202-877-8839
        • Hovedetterforsker:
          • Suthee Rapisuwon
    • Florida
      • Jacksonville, Florida, Forente stater, 32224-9980
        • Aktiv, ikke rekrutterende
        • Mayo Clinic in Florida
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University Hospital/Winship Cancer Institute
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 404-778-1868
        • Hovedetterforsker:
          • Jacqueline T. Brown
      • Atlanta, Georgia, Forente stater, 30308
        • Rekruttering
        • Emory University Hospital Midtown
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 888-946-7447
        • Hovedetterforsker:
          • Jacqueline T. Brown
      • Atlanta, Georgia, Forente stater, 30342
        • Rekruttering
        • Emory Saint Joseph's Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 404-851-7115
        • Hovedetterforsker:
          • Jacqueline T. Brown
      • Decatur, Georgia, Forente stater, 30033
    • Idaho
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • Saint Alphonsus Cancer Care Center-Nampa
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
    • Illinois
      • Alton, Illinois, Forente stater, 62002
        • Suspendert
        • OSF Saint Anthony's Health Center
      • Barrington, Illinois, Forente stater, 60010
        • Rekruttering
        • Advocate Good Shepherd Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-842-4847
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Bloomington, Illinois, Forente stater, 61704
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Bloomington
      • Burr Ridge, Illinois, Forente stater, 60527
        • Aktiv, ikke rekrutterende
        • Loyola Center for Health at Burr Ridge
      • Canton, Illinois, Forente stater, 61520
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Forente stater, 62902
        • Suspendert
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Forente stater, 62918
        • Rekruttering
        • SIH Cancer Institute
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Carthage, Illinois, Forente stater, 62321
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Forente stater, 62801
        • Suspendert
        • Centralia Oncology Clinic
      • Chicago, Illinois, Forente stater, 60657
        • Rekruttering
        • Advocate Illinois Masonic Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 773-296-5360
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Crystal Lake, Illinois, Forente stater, 60014
        • Rekruttering
        • AMG Crystal Lake - Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Danville, Illinois, Forente stater, 61832
        • Rekruttering
        • Carle at The Riverfront
        • Hovedetterforsker:
          • Prem Sobti
        • Ta kontakt med:
      • Decatur, Illinois, Forente stater, 62526
        • Rekruttering
        • Cancer Care Specialists of Illinois - Decatur
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Decatur, Illinois, Forente stater, 62526
        • Suspendert
        • Decatur Memorial Hospital
      • Dixon, Illinois, Forente stater, 61021
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Dixon
      • Downers Grove, Illinois, Forente stater, 60515
        • Rekruttering
        • Advocate Good Samaritan Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Effingham, Illinois, Forente stater, 62401
        • Rekruttering
        • Carle Physician Group-Effingham
        • Ta kontakt med:
        • Hovedetterforsker:
          • Prem Sobti
      • Effingham, Illinois, Forente stater, 62401
        • Rekruttering
        • Crossroads Cancer Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Elgin, Illinois, Forente stater, 60123
        • Rekruttering
        • Advocate Sherman Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-429-2907
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Eureka, Illinois, Forente stater, 61530
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, Forente stater, 61401
        • Suspendert
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Forente stater, 61401
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Galesburg
      • Hazel Crest, Illinois, Forente stater, 60429
        • Rekruttering
        • Advocate South Suburban Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 708-799-9995
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Homer Glen, Illinois, Forente stater, 60491
        • Aktiv, ikke rekrutterende
        • Loyola Medicine Homer Glen
      • Kewanee, Illinois, Forente stater, 61443
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Kewanee Clinic
      • Libertyville, Illinois, Forente stater, 60048
        • Rekruttering
        • AMG Libertyville - Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Macomb, Illinois, Forente stater, 61455
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Forente stater, 61938
        • Rekruttering
        • Carle Physician Group-Mattoon/Charleston
        • Ta kontakt med:
        • Hovedetterforsker:
          • Prem Sobti
      • Maywood, Illinois, Forente stater, 60153
        • Aktiv, ikke rekrutterende
        • Loyola University Medical Center
      • Melrose Park, Illinois, Forente stater, 60160
        • Aktiv, ikke rekrutterende
        • Marjorie Weinberg Cancer Center at Loyola-Gottlieb
      • Mount Vernon, Illinois, Forente stater, 62864
        • Rekruttering
        • SSM Health Good Samaritan
        • Hovedetterforsker:
          • Jay W. Carlson
        • Ta kontakt med:
      • O'Fallon, Illinois, Forente stater, 62269
        • Rekruttering
        • Cancer Care Center of O'Fallon
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
      • Oak Lawn, Illinois, Forente stater, 60453-2699
        • Rekruttering
        • Advocate Christ Medical Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-323-8622
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Ottawa, Illinois, Forente stater, 61350
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Ottawa Clinic
      • Park Ridge, Illinois, Forente stater, 60068
        • Rekruttering
        • Advocate Lutheran General Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 847-384-3621
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Pekin, Illinois, Forente stater, 61554
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Forente stater, 61636
        • Suspendert
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Forente stater, 61615
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Forente stater, 61354
        • Suspendert
        • Valley Radiation Oncology
      • Peru, Illinois, Forente stater, 61354
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Peru
      • Princeton, Illinois, Forente stater, 61356
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Forente stater, 62702
        • Rekruttering
        • Southern Illinois University School of Medicine
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 217-545-7929
      • Springfield, Illinois, Forente stater, 62702
        • Rekruttering
        • Springfield Clinic
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-444-7541
      • Springfield, Illinois, Forente stater, 62781
        • Suspendert
        • Springfield Memorial Hospital
      • Urbana, Illinois, Forente stater, 61801
        • Rekruttering
        • Carle Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Prem Sobti
      • Washington, Illinois, Forente stater, 61571
        • Aktiv, ikke rekrutterende
        • Illinois CancerCare - Washington
    • Indiana
      • Richmond, Indiana, Forente stater, 47374
        • Aktiv, ikke rekrutterende
        • Reid Health
    • Iowa
      • Ames, Iowa, Forente stater, 50010
        • Aktiv, ikke rekrutterende
        • Mary Greeley Medical Center
      • Ames, Iowa, Forente stater, 50010
        • Aktiv, ikke rekrutterende
        • McFarland Clinic - Ames
      • Bettendorf, Iowa, Forente stater, 52722
        • Rekruttering
        • University of Iowa Healthcare Cancer Services Quad Cities
        • Hovedetterforsker:
          • Fernando Maciel Barbosa
        • Ta kontakt med:
      • Boone, Iowa, Forente stater, 50036
        • Aktiv, ikke rekrutterende
        • McFarland Clinic - Boone
      • Fort Dodge, Iowa, Forente stater, 50501
        • Aktiv, ikke rekrutterende
        • McFarland Clinic - Trinity Cancer Center
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Hovedetterforsker:
          • Fernando Maciel Barbosa
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
      • Jefferson, Iowa, Forente stater, 50129
        • Aktiv, ikke rekrutterende
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Forente stater, 50158
        • Aktiv, ikke rekrutterende
        • McFarland Clinic - Marshalltown
    • Kansas
      • Garden City, Kansas, Forente stater, 67846
        • Suspendert
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Forente stater, 67530
        • Suspendert
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Rekruttering
        • University of Kentucky/Markey Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 859-257-3379
        • Hovedetterforsker:
          • Patrick J. Hensley
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70809
        • Rekruttering
        • Mary Bird Perkins Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Victor T. Lin
      • Metairie, Louisiana, Forente stater, 70006
        • Rekruttering
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rajasree P. Chowdry
      • Metairie, Louisiana, Forente stater, 70006
        • Suspendert
        • East Jefferson General Hospital
      • Metairie, Louisiana, Forente stater, 70002
        • Rekruttering
        • Mary Bird Perkins Cancer Center - Metairie
        • Hovedetterforsker:
          • Victor T. Lin
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 504-584-6990
      • New Orleans, Louisiana, Forente stater, 70112
        • Rekruttering
        • University Medical Center New Orleans
        • Ta kontakt med:
        • Hovedetterforsker:
          • Rajasree P. Chowdry
    • Maine
      • Augusta, Maine, Forente stater, 04330
        • Rekruttering
        • Harold Alfond Center for Cancer Care
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 207-626-4855
        • Hovedetterforsker:
          • Erin Adler
      • Biddeford, Maine, Forente stater, 04005
        • Suspendert
        • MaineHealth Maine Medical Center - Biddeford
      • Sanford, Maine, Forente stater, 04073
        • Rekruttering
        • MaineHealth Cancer Care Center of York County
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 207-459-1600
        • Hovedetterforsker:
          • Erin Adler
      • Sanford, Maine, Forente stater, 04073
        • Rekruttering
        • MaineHealth Cancer Care and IV Therapy - Sanford
        • Ta kontakt med:
        • Hovedetterforsker:
          • Erin Adler
      • Scarborough, Maine, Forente stater, 04074
        • Rekruttering
        • MaineHealth Maine Medical Center- Scarborough
        • Ta kontakt med:
        • Hovedetterforsker:
          • Erin Adler
      • South Portland, Maine, Forente stater, 04106
        • Rekruttering
        • MaineHealth Cancer Care and IV Therapy - South Portland
        • Ta kontakt med:
        • Hovedetterforsker:
          • Erin Adler
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Rekruttering
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jean H. Hoffman-Censits
    • Massachusetts
      • Worcester, Massachusetts, Forente stater, 01655
        • Rekruttering
        • UMass Memorial Medical Center - University Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kriti Mittal
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48106
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Brighton, Michigan, Forente stater, 48114
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Brighton, Michigan, Forente stater, 48114
        • Rekruttering
        • Trinity Health Medical Center - Brighton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Canton, Michigan, Forente stater, 48188
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Canton, Michigan, Forente stater, 48188
        • Rekruttering
        • Trinity Health Medical Center - Canton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Chelsea, Michigan, Forente stater, 48118
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Chelsea, Michigan, Forente stater, 48118
      • Clarkston, Michigan, Forente stater, 48346
        • Rekruttering
        • Hematology Oncology Consultants-Clarkston
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Clarkston, Michigan, Forente stater, 48346
        • Suspendert
        • Newland Medical Associates-Clarkston
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Genesys Hurley Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Hurley Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Flint, Michigan, Forente stater, 48503
        • Suspendert
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Forente stater, 48503
        • Rekruttering
        • Cancer Hematology Centers - Flint
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Livonia, Michigan, Forente stater, 48154
        • Suspendert
        • Hope Cancer Clinic
      • Livonia, Michigan, Forente stater, 48154
        • Rekruttering
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Macomb, Michigan, Forente stater, 48044
        • Rekruttering
        • Henry Ford Saint John Hospital - Macomb Medical
        • Hovedetterforsker:
          • Elie G. Dib
        • Ta kontakt med:
      • Pontiac, Michigan, Forente stater, 48341
        • Rekruttering
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Pontiac, Michigan, Forente stater, 48341
        • Rekruttering
        • Michigan Healthcare Professionals Pontiac
        • Hovedetterforsker:
          • Elie G. Dib
        • Ta kontakt med:
      • Pontiac, Michigan, Forente stater, 48341
        • Rekruttering
        • Trinity Health IHA Medical Group-Alice Gustafson Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
      • Saginaw, Michigan, Forente stater, 48604
        • Suspendert
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Forente stater, 48601
      • Tawas City, Michigan, Forente stater, 48764
      • West Branch, Michigan, Forente stater, 48661
        • Suspendert
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, Forente stater, 48106
      • Ypsilanti, Michigan, Forente stater, 48197
        • Rekruttering
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elie G. Dib
    • Minnesota
      • Burnsville, Minnesota, Forente stater, 55337
        • Suspendert
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, Forente stater, 55337
        • Suspendert
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, Forente stater, 55008
        • Suspendert
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Rekruttering
        • Mercy Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Edina, Minnesota, Forente stater, 55435
        • Suspendert
        • Fairview Southdale Hospital
      • Edina, Minnesota, Forente stater, 55435
        • Rekruttering
        • Minnesota Oncology - Edina
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Fridley, Minnesota, Forente stater, 55432
        • Aktiv, ikke rekrutterende
        • Unity Hospital
      • Maple Grove, Minnesota, Forente stater, 55369
        • Suspendert
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, Forente stater, 55109
        • Rekruttering
        • Minnesota Oncology Hematology PA-Maplewood
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Maplewood, Minnesota, Forente stater, 55109
        • Suspendert
        • Saint John's Hospital - Healtheast
      • Minneapolis, Minnesota, Forente stater, 55407
        • Suspendert
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Forente stater, 55415
        • Suspendert
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Forente stater, 55454
        • Suspendert
        • Health Partners Inc
      • Monticello, Minnesota, Forente stater, 55362
        • Suspendert
        • Monticello Cancer Center
      • New Ulm, Minnesota, Forente stater, 56073
        • Suspendert
        • New Ulm Medical Center
      • Princeton, Minnesota, Forente stater, 55371
        • Suspendert
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, Forente stater, 55422
        • Suspendert
        • North Memorial Medical Health Center
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 855-776-0015
        • Hovedetterforsker:
          • Lance C. Pagliaro
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • Rekruttering
        • Park Nicollet Clinic - Saint Louis Park
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forente stater, 55101
        • Rekruttering
        • Regions Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Saint Paul, Minnesota, Forente stater, 55102
        • Suspendert
        • United Hospital
      • Shakopee, Minnesota, Forente stater, 55379
        • Suspendert
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, Forente stater, 55082
        • Rekruttering
        • Lakeview Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Waconia, Minnesota, Forente stater, 55387
        • Suspendert
        • Ridgeview Medical Center
      • Willmar, Minnesota, Forente stater, 56201
        • Suspendert
        • Rice Memorial Hospital
      • Woodbury, Minnesota, Forente stater, 55125
        • Rekruttering
        • Minnesota Oncology Hematology PA-Woodbury
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M. King
      • Wyoming, Minnesota, Forente stater, 55092
        • Suspendert
        • Fairview Lakes Medical Center
    • Missouri
      • Ballwin, Missouri, Forente stater, 63011
        • Suspendert
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Forente stater, 65613
        • Suspendert
        • Central Care Cancer Center - Bolivar
      • Cape Girardeau, Missouri, Forente stater, 63703
        • Rekruttering
        • Saint Francis Medical Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 573-334-2230
          • E-post: sfmc@sfmc.net
      • Cape Girardeau, Missouri, Forente stater, 63703
        • Suspendert
        • Mercy Cancer Center - Cape Girardeau
      • Farmington, Missouri, Forente stater, 63640
        • Rekruttering
        • Parkland Health Center - Farmington
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Jefferson City, Missouri, Forente stater, 65109
        • Suspendert
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Forente stater, 64804
        • Suspendert
        • Freeman Health System
      • Joplin, Missouri, Forente stater, 64804
        • Suspendert
        • Mercy Hospital Joplin
      • Rolla, Missouri, Forente stater, 65401
        • Suspendert
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Forente stater, 65401
        • Suspendert
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Forente stater, 64506
        • Suspendert
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Forente stater, 63670
        • Rekruttering
        • Sainte Genevieve County Memorial Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Springfield, Missouri, Forente stater, 65804
        • Suspendert
        • Mercy Hospital Springfield
      • Springfield, Missouri, Forente stater, 65807
        • Suspendert
        • CoxHealth South Hospital
      • St Louis, Missouri, Forente stater, 63128
        • Rekruttering
        • Mercy Hospital South
        • Hovedetterforsker:
          • Jay W. Carlson
        • Ta kontakt med:
      • St Louis, Missouri, Forente stater, 63141
        • Rekruttering
        • Mercy Hospital Saint Louis
        • Hovedetterforsker:
          • Jay W. Carlson
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-251-7066
      • St Louis, Missouri, Forente stater, 63109
        • Suspendert
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Forente stater, 63131
        • Rekruttering
        • Missouri Baptist Medical Center
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Sullivan, Missouri, Forente stater, 63080
        • Rekruttering
        • Missouri Baptist Sullivan Hospital
        • Hovedetterforsker:
          • Bryan A. Faller
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 314-996-5569
      • Washington, Missouri, Forente stater, 63090
        • Suspendert
        • Mercy Hospital Washington
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89102
        • Suspendert
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Forente stater, 89183
        • Suspendert
        • OptumCare Cancer Care at Fort Apache
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • Fullført
        • Hackensack University Medical Center
      • Livingston, New Jersey, Forente stater, 07039
        • Rekruttering
        • Cooperman Barnabas Medical Center
        • Hovedetterforsker:
          • Saum B. Ghodoussipour
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 973-322-5200
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
        • Hovedetterforsker:
          • Saum B. Ghodoussipour
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 732-235-7356
      • Toms River, New Jersey, Forente stater, 08755
        • Rekruttering
        • Community Medical Center
        • Hovedetterforsker:
          • Saum B. Ghodoussipour
        • Ta kontakt med:
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • Rekruttering
        • University of New Mexico Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy C. Tarnower
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Aktiv, ikke rekrutterende
        • Roswell Park Cancer Institute
    • North Carolina
      • Clinton, North Carolina, Forente stater, 28328
        • Rekruttering
        • Southeastern Medical Oncology Center-Clinton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Samer S. Kasbari
      • Goldsboro, North Carolina, Forente stater, 27534
        • Rekruttering
        • Southeastern Medical Oncology Center-Goldsboro
        • Ta kontakt med:
        • Hovedetterforsker:
          • Samer S. Kasbari
      • Jacksonville, North Carolina, Forente stater, 28546
        • Rekruttering
        • Southeastern Medical Oncology Center-Jacksonville
        • Hovedetterforsker:
          • Samer S. Kasbari
        • Ta kontakt med:
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Aktiv, ikke rekrutterende
        • Wake Forest University Health Sciences
    • Ohio
      • Centerville, Ohio, Forente stater, 45459
        • Rekruttering
        • Miami Valley Hospital South
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tarek M. Sabagh
      • Centerville, Ohio, Forente stater, 45459
        • Aktiv, ikke rekrutterende
        • Dayton Physicians LLC-Miami Valley South
      • Dayton, Ohio, Forente stater, 45409
        • Rekruttering
        • Miami Valley Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tarek M. Sabagh
      • Dayton, Ohio, Forente stater, 45415
        • Rekruttering
        • Miami Valley Hospital North
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tarek M. Sabagh
      • Dayton, Ohio, Forente stater, 45409
        • Rekruttering
        • Premier Blood and Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 937-276-8320
        • Hovedetterforsker:
          • Tarek M. Sabagh
      • Dayton, Ohio, Forente stater, 45415
        • Aktiv, ikke rekrutterende
        • Dayton Physician LLC - Englewood
      • Findlay, Ohio, Forente stater, 45840
        • Aktiv, ikke rekrutterende
        • Armes Family Cancer Center
      • Franklin, Ohio, Forente stater, 45005-1066
        • Rekruttering
        • Atrium Medical Center-Middletown Regional Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tarek M. Sabagh
      • Franklin, Ohio, Forente stater, 45005
        • Aktiv, ikke rekrutterende
        • Dayton Physicians LLC-Atrium
      • Greenville, Ohio, Forente stater, 45331
        • Rekruttering
        • Miami Valley Cancer Care and Infusion
        • Hovedetterforsker:
          • Tarek M. Sabagh
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 937-569-7515
      • Kettering, Ohio, Forente stater, 45409
        • Aktiv, ikke rekrutterende
        • Greater Dayton Cancer Center
      • Kettering, Ohio, Forente stater, 45429
        • Aktiv, ikke rekrutterende
        • Kettering Medical Center
      • Springfield, Ohio, Forente stater, 45504
        • Suspendert
        • Springfield Regional Cancer Center
      • Sylvania, Ohio, Forente stater, 43560
        • Rekruttering
        • ProMedica Flower Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jeffrey H. Muler
      • Troy, Ohio, Forente stater, 45373
        • Rekruttering
        • Upper Valley Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tarek M. Sabagh
    • Oklahoma
      • Lawton, Oklahoma, Forente stater, 73505
        • Rekruttering
        • Cancer Centers of Southwest Oklahoma Research
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 877-231-4440
        • Hovedetterforsker:
          • Adanma Anji Ayanambakkam Attanathi
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adanma Anji Ayanambakkam Attanathi
      • Oklahoma City, Oklahoma, Forente stater, 73120
        • Suspendert
        • Mercy Hospital Oklahoma City
    • Pennsylvania
      • Erie, Pennsylvania, Forente stater, 16505
        • Rekruttering
        • UPMC Hillman Cancer Center Erie
        • Hovedetterforsker:
          • Leonard J. Appleman
        • Ta kontakt med:
      • Greensburg, Pennsylvania, Forente stater, 15601
        • Rekruttering
        • UPMC Cancer Centers - Arnold Palmer Pavilion
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 724-838-1900
        • Hovedetterforsker:
          • Leonard J. Appleman
      • Hershey, Pennsylvania, Forente stater, 17033-0850
        • Rekruttering
        • Penn State Milton S Hershey Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Monika Joshi
      • Monroeville, Pennsylvania, Forente stater, 15146
        • Rekruttering
        • UPMC Hillman Cancer Center - Monroeville
        • Hovedetterforsker:
          • Leonard J. Appleman
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Thomas Jefferson University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • William J. Tester
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania/Abramson Cancer Center
        • Hovedetterforsker:
          • Ronac Mamtani
        • Ta kontakt med:
      • Pittsburgh, Pennsylvania, Forente stater, 15237
        • Rekruttering
        • UPMC-Passavant Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-367-6454
        • Hovedetterforsker:
          • Leonard J. Appleman
      • Pittsburgh, Pennsylvania, Forente stater, 15243
        • Rekruttering
        • UPMC-Saint Clair Hospital Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-502-3920
        • Hovedetterforsker:
          • Leonard J. Appleman
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • UPMC Hillman Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Hovedetterforsker:
          • Leonard J. Appleman
      • Washington, Pennsylvania, Forente stater, 15301
        • Rekruttering
        • UPMC Cancer Center-Washington
        • Ta kontakt med:
        • Hovedetterforsker:
          • Leonard J. Appleman
      • West Reading, Pennsylvania, Forente stater, 19611
        • Rekruttering
        • Reading Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 610-988-9323
        • Hovedetterforsker:
          • Terrence P. Cescon
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Aktiv, ikke rekrutterende
        • Medical University of South Carolina
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • Rekruttering
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vitaly Margulis
      • Dallas, Texas, Forente stater, 75235
        • Rekruttering
        • Parkland Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vitaly Margulis
      • Dallas, Texas, Forente stater, 75237
        • Suspendert
        • UT Southwestern Simmons Cancer Center - RedBird
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vitaly Margulis
      • Richardson, Texas, Forente stater, 75080
        • Rekruttering
        • UT Southwestern Clinical Center at Richardson/Plano
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vitaly Margulis
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center - Montlake
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-804-8824
        • Hovedetterforsker:
          • Petros Grivas
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-804-8824
        • Hovedetterforsker:
          • Petros Grivas
    • West Virginia
      • Charleston, West Virginia, Forente stater, 25304
        • Rekruttering
        • Vandalia Health/CAMC Institute for Academic Medicine
        • Hovedetterforsker:
          • Kok Hoe Chan
        • Ta kontakt med:
    • Wisconsin
      • Appleton, Wisconsin, Forente stater, 54911
        • Rekruttering
        • ThedaCare Regional Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthias Weiss
      • Burlington, Wisconsin, Forente stater, 53105
        • Rekruttering
        • Aurora Cancer Care-Southern Lakes VLCC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Eau Claire, Wisconsin, Forente stater, 54701
      • Germantown, Wisconsin, Forente stater, 53022
        • Rekruttering
        • Aurora Health Care Germantown Health Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Grafton, Wisconsin, Forente stater, 53024
        • Rekruttering
        • Aurora Cancer Care-Grafton
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Green Bay, Wisconsin, Forente stater, 54311
        • Rekruttering
        • Aurora BayCare Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Kenosha, Wisconsin, Forente stater, 53142
        • Rekruttering
        • Aurora Cancer Care-Kenosha South
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Marinette, Wisconsin, Forente stater, 54143
        • Rekruttering
        • Aurora Bay Area Medical Group-Marinette
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Marshfield, Wisconsin, Forente stater, 54449
      • Milwaukee, Wisconsin, Forente stater, 53209
        • Rekruttering
        • Aurora Cancer Care-Milwaukee
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Forente stater, 53215
        • Rekruttering
        • Aurora Saint Luke's Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Forente stater, 53233
        • Rekruttering
        • Aurora Sinai Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Minocqua, Wisconsin, Forente stater, 54548
      • Mukwonago, Wisconsin, Forente stater, 53149
        • Rekruttering
        • ProHealth D N Greenwald Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Timothy R. Wassenaar
      • New Richmond, Wisconsin, Forente stater, 54017
        • Suspendert
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Forente stater, 53066
        • Rekruttering
        • ProHealth Oconomowoc Memorial Hospital
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 262-928-7878
      • Oshkosh, Wisconsin, Forente stater, 54904
        • Rekruttering
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Racine, Wisconsin, Forente stater, 53406
        • Rekruttering
        • Aurora Cancer Care-Racine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Rice Lake, Wisconsin, Forente stater, 54868
      • Sheboygan, Wisconsin, Forente stater, 53081
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Sheboygan
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Stevens Point, Wisconsin, Forente stater, 54482
      • Summit, Wisconsin, Forente stater, 53066
        • Rekruttering
        • Aurora Medical Center in Summit
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Two Rivers, Wisconsin, Forente stater, 54241
        • Rekruttering
        • Vince Lombardi Cancer Clinic-Two Rivers
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Waukesha, Wisconsin, Forente stater, 53188
        • Rekruttering
        • ProHealth Waukesha Memorial Hospital
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 262-928-7632
      • Waukesha, Wisconsin, Forente stater, 53188
        • Rekruttering
        • UW Cancer Center at ProHealth Care
        • Hovedetterforsker:
          • Timothy R. Wassenaar
        • Ta kontakt med:
      • Waupaca, Wisconsin, Forente stater, 54981
        • Rekruttering
        • ThedaCare Cancer Care - Waupaca
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthias Weiss
      • Wauwatosa, Wisconsin, Forente stater, 53226
        • Rekruttering
        • Aurora Cancer Care-Milwaukee West
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • West Allis, Wisconsin, Forente stater, 53227
        • Rekruttering
        • Aurora West Allis Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas J. Saphner
      • Weston, Wisconsin, Forente stater, 54476

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • STEP 1 REGISTRATION AND RANDOMIZATION

  • Patients must be >= 18 years of age

  • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

  • Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:

    • Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy

    • High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy

      • NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)

        • Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
  • Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma

  • Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)

  • Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)

  • Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)

  • Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)

    • NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
  • Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment

  • Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).

    • NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
  • Patient must meet below criteria for prior/current malignancy history:

    • Non-urothelial cancer malignancy history:

      • Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat

        • NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
      • Urothelial cancer malignancy history:

        • Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
        • T0, Ta or Tis at any time
        • T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
        • Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
        • NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
  • Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements

  • Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases

  • Patient must not have received prior systemic anthracycline therapy

    • NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
  • Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible

  • Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:

    • Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
    • Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial

    • NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
    • NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

    • NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab

  • Patient must not have had a major surgical procedure within 28 days prior to registration/randomization

    • NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
  • Patient must not have history of allogenic organ transplantation

  • Patient must have a body weight of > 30 kg

  • Patient must have life expectancy of >= 12 weeks

  • Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization

    • NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C

      • Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:

        • Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
        • Hearing loss >= 3
        • Neuropathy >= 2
        • ECOG performance status 2
      • In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration

      • Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:

        • Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
        • ECOG performance status 0-1
        • Hearing loss grade 0-2
        • Neuropathy 0-1
      • In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization

      • Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A (durvalumab, chemotherapy)

Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.

Given IV

Andre navn:
  • CDDP
  • Cis-diammindikloridplatina
  • Cismaplat
  • Cisplatinum
  • Neoplatin
  • Platinol
  • Abiplatin
  • Blastolem
  • Briplatin
  • Cis-diammin-diklorplatina
  • Cis-diamindiklor platina (II)
  • Cis-diamindiklorplatina
  • Cis-dikloramin platina (II)
  • Cis-platinøs diamin diklorid
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diamin diklorid
  • Cisplatina
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Peyrones klorid
  • Peyrones salt
  • Placis
  • Plastistil
  • Platamin
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platina
  • Platina diaminodiklorid
  • Platiran
  • Platistin
  • Platosin

Undergo blood sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Abitrexate
  • Folex
  • Mexate
  • MTX
  • Alfa-metopterin
  • Amethopterin
  • Brimexat
  • CL 14377
  • CL-14377
  • Emtexate
  • Emthexat
  • Emthexate
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertreksat
  • Lumexon
  • Maxtrex
  • Medsatrexate
  • Metex
  • Metoblastin
  • Metotreksat LPF
  • Metotreksat Metylaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo MRI

Andre navn:
  • MR
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medisinsk bildebehandling, magnetisk resonans / kjernemagnetisk resonans
  • MR Imaging
  • MR-skanning
  • NMR-avbildning
  • NMRI
  • Kjernemagnetisk resonansavbildning
  • Magnetisk resonanstomografi (MR)
  • sMRI
  • Magnetisk resonansavbildning (prosedyre)
  • MR-er
  • Strukturell MR

Undergo surgery

Undergo tissue biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given IV

Andre navn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kjede, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736

Given Iv

Andre navn:
  • Adriamycin
  • 5,12-naftacendion, 10-[(3-amino-2,3,6-trideoksy-alfa-L-lyxo-heksopyranosyl)oksy]-7,8, 9,10-tetrahydro-6,8,11-trihydroksy -8-(hydroksyacetyl)-1-metoksy-, hydroklorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydroklorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROKLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroksydaunorubicin
  • Rubex
  • FI106

Given via injection

Andre navn:
  • Filgrastim SD-01
  • filgrastim-SD/01
  • Fulphila
  • HSP-130
  • Jinyouli
  • Neulasta
  • Neulastim
  • Nyvepria
  • PEG-filgrastim
  • Pegcyte
  • Pegfilgrastim Biosimilar HSP-130
  • Pegfilgrastim Biosimilar Nyvepria
  • Pegfilgrastim Biosimilar Pegcyte
  • Pegfilgrastim Biosimilar PF-06881894
  • Pegfilgrastim Biosimilar Udenyca
  • Pegfilgrastim Biosimilar Ziextenzo
  • Pegfilgrastim-jmdb
  • PF-06881894
  • SD-01
  • SD-01 vedvarende varighet G-CSF
  • Udenyca
  • Ziextenzo
  • Neupopeg
  • Pegylert G-CSF
  • Pegylert GCSF
  • Pegylert granulocyttkolonistimulerende faktor
  • Pegfilgrastim-apgf
  • Pegfilgrastim-bmez
  • Pegfilgrastim-cbqv
  • Dulastin
  • Tripegfilgrastim
  • Fylnetra
  • G-Lasta
  • Pegfilgrastim-fpgk
  • Pegfilgrastim-pbbk
  • Stimufeng
  • Pegfilgrastim-cegf
  • Pegfilgrastim-dyru
  • Pegfilgrastim-gras
  • Pegfilgrastim-pelg
  • Pegfilgrastim-pelm
  • Cegfila
  • Dyrupeg
  • Grasustek
  • Pelgraz
  • Pelmeg

Given Iv

Andre navn:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE
Aktiv komparator: Arm B (chemotherapy)

Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.

Given IV

Andre navn:
  • CDDP
  • Cis-diammindikloridplatina
  • Cismaplat
  • Cisplatinum
  • Neoplatin
  • Platinol
  • Abiplatin
  • Blastolem
  • Briplatin
  • Cis-diammin-diklorplatina
  • Cis-diamindiklor platina (II)
  • Cis-diamindiklorplatina
  • Cis-dikloramin platina (II)
  • Cis-platinøs diamin diklorid
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diamin diklorid
  • Cisplatina
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Peyrones klorid
  • Peyrones salt
  • Placis
  • Plastistil
  • Platamin
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platina
  • Platina diaminodiklorid
  • Platiran
  • Platistin
  • Platosin

Undergo blood sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Given IV

Andre navn:
  • Abitrexate
  • Folex
  • Mexate
  • MTX
  • Alfa-metopterin
  • Amethopterin
  • Brimexat
  • CL 14377
  • CL-14377
  • Emtexate
  • Emthexat
  • Emthexate
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertreksat
  • Lumexon
  • Maxtrex
  • Medsatrexate
  • Metex
  • Metoblastin
  • Metotreksat LPF
  • Metotreksat Metylaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo MRI

Andre navn:
  • MR
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medisinsk bildebehandling, magnetisk resonans / kjernemagnetisk resonans
  • MR Imaging
  • MR-skanning
  • NMR-avbildning
  • NMRI
  • Kjernemagnetisk resonansavbildning
  • Magnetisk resonanstomografi (MR)
  • sMRI
  • Magnetisk resonansavbildning (prosedyre)
  • MR-er
  • Strukturell MR

Undergo surgery

Undergo tissue biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given Iv

Andre navn:
  • Adriamycin
  • 5,12-naftacendion, 10-[(3-amino-2,3,6-trideoksy-alfa-L-lyxo-heksopyranosyl)oksy]-7,8, 9,10-tetrahydro-6,8,11-trihydroksy -8-(hydroksyacetyl)-1-metoksy-, hydroklorid, (8S-cis)- (9Cl)
  • ADM
  • Adriacin
  • Adriamycin hydroklorid
  • Adriamycin PFS
  • Adriamycin RDF
  • ADRIAMYCIN, HYDROKLORID
  • Adriblastina
  • Adriblastin
  • Adrimedac
  • Chloridrato de Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicin HCl
  • Doxorubicin.HCl
  • Doxorubin
  • Farmiblastina
  • FI 106
  • FI-106
  • hydroksydaunorubicin
  • Rubex
  • FI106

Given via injection

Andre navn:
  • Filgrastim SD-01
  • filgrastim-SD/01
  • Fulphila
  • HSP-130
  • Jinyouli
  • Neulasta
  • Neulastim
  • Nyvepria
  • PEG-filgrastim
  • Pegcyte
  • Pegfilgrastim Biosimilar HSP-130
  • Pegfilgrastim Biosimilar Nyvepria
  • Pegfilgrastim Biosimilar Pegcyte
  • Pegfilgrastim Biosimilar PF-06881894
  • Pegfilgrastim Biosimilar Udenyca
  • Pegfilgrastim Biosimilar Ziextenzo
  • Pegfilgrastim-jmdb
  • PF-06881894
  • SD-01
  • SD-01 vedvarende varighet G-CSF
  • Udenyca
  • Ziextenzo
  • Neupopeg
  • Pegylert G-CSF
  • Pegylert GCSF
  • Pegylert granulocyttkolonistimulerende faktor
  • Pegfilgrastim-apgf
  • Pegfilgrastim-bmez
  • Pegfilgrastim-cbqv
  • Dulastin
  • Tripegfilgrastim
  • Fylnetra
  • G-Lasta
  • Pegfilgrastim-fpgk
  • Pegfilgrastim-pbbk
  • Stimufeng
  • Pegfilgrastim-cegf
  • Pegfilgrastim-dyru
  • Pegfilgrastim-gras
  • Pegfilgrastim-pelg
  • Pegfilgrastim-pelm
  • Cegfila
  • Dyrupeg
  • Grasustek
  • Pelgraz
  • Pelmeg

Given Iv

Andre navn:
  • 29060 LE
  • 29060-LE
  • Exal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE
Eksperimentell: Arm C (durvalumab, gemcitabine hydrochloride)

Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.

Undergo blood sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo MRI

Andre navn:
  • MR
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medisinsk bildebehandling, magnetisk resonans / kjernemagnetisk resonans
  • MR Imaging
  • MR-skanning
  • NMR-avbildning
  • NMRI
  • Kjernemagnetisk resonansavbildning
  • Magnetisk resonanstomografi (MR)
  • sMRI
  • Magnetisk resonansavbildning (prosedyre)
  • MR-er
  • Strukturell MR

Given IV

Andre navn:
  • Gemzar
  • dFdCyd
  • Difluordeoksycytidinhydroklorid
  • Gemcitabin HCI
  • LY-188011
  • LY188011
  • LY 188011

Undergo surgery

Undergo tissue biopsy

Andre navn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Given IV

Andre navn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kjede, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Tidsramme: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years

Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS.

From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Tidsramme: At surgery

Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders.

At surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
pCR (Cisplatin-kvalifisert kohort: arm A og B)
Tidsramme: Inntil 5 år
Inntil 5 år
EFS (cisplatin-ineligible cohort: Arm C)
Tidsramme: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years

Will be characterized using the Kaplan-Meier method.

From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
Overall survival (OS) (All Patients)
Tidsramme: From registration/randomization to death from any cause, assessed up to 5 years

OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method.

From registration/randomization to death from any cause, assessed up to 5 years
Urothelial cancer-free survival or disease-free survival (All Patients)
Tidsramme: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years

A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment.

From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
Cancer-specific survival (All Patients)
Tidsramme: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years

Will be analyzed using Gray's method and cumulative incidence estimates will be reported.

From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Tidsramme: Post chemotherapy and post surgery

The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy.

Post chemotherapy and post surgery
Incidence of adverse events (All Patients)
Tidsramme: Up to 30 days post surgery

Toxicity will be evaluated in all treated patients.

Up to 30 days post surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. november 2021

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

30. september 2027

Datoer for studieregistrering

Først innsendt

13. november 2020

Først innsendt som oppfylte QC-kriteriene

13. november 2020

Først lagt ut (Faktiske)

16. november 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NCI-2020-09850
  • U10CA180820 (U.S. NIH-stipend/kontrakt)
  • NCI-2020-09850 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • EA8192 (Annen identifikator: CTEP)
  • EA8192 (Annen identifikator: ECOG-ACRIN Cancer Research Group)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere